Phase 3 Liver Cancer Trial, Recruiting NCT05794971 Sponsor: Sun Yat-sen University Condition: Liver Cancer
Back to Liver Cancer

Phase 3 Liver Cancer Trial, Recruiting

NCT05794971
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older, of any race or sex, whose colorectal cancer has spread to the liver, confirmed by biopsy or imaging
  • People whose cancer has continued to grow or spread after trying two different standard chemotherapy treatments
  • People who have at least one liver tumour measuring more than 1 cm
  • People whose cancer is mostly in the liver, meaning at least 80% of the tumour burden is located there
  • People whose liver tumours take up less than 60% of the total liver
  • People who are generally able to carry out daily activities with little or no restriction (confirm with trial site regarding exact fitness score required)
  • People whose liver is functioning at a certain level, assessed by a scoring system called Child-Pugh grade A or B (confirm with trial site)
  • People whose life expectancy is estimated to be more than 3 months
  • People whose blood counts and kidney and liver function fall within acceptable ranges on blood tests
  • Women who are not pregnant, with a negative pregnancy blood test, and who are using acceptable contraception if able to become pregnant
  • Men who are fertile and using effective contraception
  • People who are willing and able to provide signed written consent to participate

Who may not be able to join:

  • People who have previously been treated with TACE (a liver-directed procedure), or the medications regorafenib or fruquintinib
  • People whose cancer has spread to the brain
  • People with serious conditions affecting the heart, kidneys, bone marrow, lungs, or nervous system
  • People who have or have had another type of cancer
  • People with a serious illness or certain chronic conditions such as tuberculosis (TB) or HIV/AIDS
  • People with a known or suspected allergy to any of the medications used in this trial
  • Women who are pregnant or breastfeeding
  • People with serious physical or mental health conditions that could interfere with taking part in the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Bo Zhang, M.D, Sixth Affiliated Hospital, Sun Yat-sen University

Phone: 86-13660397903

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
10 June 2023
Est. completion
31 March 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Overall Survival (OS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov